Svetlana Shulga‐Morskaya

Statistics

Publications

Citations

3.1K

H-Index

Active since

1998

Affiliations

Alnylam Pharmaceuticals (United States)(Current)

Biogen (United States)

Harvard University

Svetlana Shulga‐Morskaya is an author at Alnylam Pharmaceuticals (United States) specializing in life sciences, molecular biology, and rna interference.

Publications per year

1998–2022

Publications

An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway

Barbara J. Schiemann, Jennifer L. Gommerman, Kalpit A. Vora et al. · Science · 2001 · 1.1K citations

Life Sciences, Cell Biology, Immunology +14

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya et al. · The Lancet · 2013 · 574 citations

Life Sciences, Biochemistry, Pharmacology +16

Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates

Christopher R. Brown, Swati Gupta, June Qin et al. · Nucleic Acids Research · 2020 · 277 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity

Maja M. Janas, Mark K. Schlegel, Carole E. Harbison et al. · Nature Communications · 2018 · 266 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

B Cell-Activating Factor Belonging to the TNF Family Acts through Separate Receptors to Support B Cell Survival and T Cell-Independent Antibody Formation

Svetlana Shulga‐Morskaya, Max Dobles, Meghan E. Walsh et al. · The Journal of Immunology · 2004 · 252 citations · Full text

Life Sciences, Immunology, Molecular Biology +12

1–5 of 13